Key result
Portal hypertension significantly reduced myosin phosphorylation in maximally stimulated mesenteric arteries (19.9% vs 43.8% in sham controls) and decreased RhoA expression.
Why the study?
Does PKA inhibition with Rp-cAMPS improve agonist-induced myosin phosphorylation and RhoA expression in the mesenteric vasculature of rats with portal hypertension?
Does PKA inhibition with Rp-cAMPS improve agonist-induced myosin phosphorylation and RhoA expression in the mesenteric vasculature of rats with portal hypertension?
Absolute Event Rate: 19.9% vs 43.8%
Reductions in membrane-associated RhoA expression, regulated by cAMP-dependent events, lead to reduced myosin phosphorylation and may underlie reduced vasoconstrictor effectiveness in portal hypertensive resistance vasculature.
No takes yet. Share an insight, caveat, or question.
May impair mesenteric vasoconstriction in portal hypertension; hypothesis-generating for PKA-targeted interventions in cirrhosis models.
Zhang et al. (2004) studied Portal hypertension (animal model). Portal hypertension (via portal vein stenosis) vs. Sham-operated control was evaluated on Myosin phosphorylation in maximally stimulated first-order mesenteric arteries. Portal hypertension significantly reduced myosin phosphorylation in maximally stimulated mesenteric arteries (19.9% vs 43.8% in sham controls) and decreased RhoA expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: